Seroatlas · Human Serome Atlas

SFT2D3

Vesicle transport protein SFT2C

Also known as: MGC5391, SFT2C_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q587I9
Gene: SFT2D3
Ensembl: ENSG00000173349
Chromosome: 2
Canonical length: 215 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Predicted to be involved in protein transport and vesicle-mediated transport. Predicted to be located in several cellular components, including cytoplasm; endomembrane system; and intracellular membrane-bounded organelle. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

215 residues, UniProt reviewed canonical sequence.

>Q587I9|SFT2D3
     1  MADLHRQLQE YLAQGKAGGP AAAEPLLAAE KAEEPGDRPA EEWLGRAGLR WTWARSPAES
    61  AAAGLTCLPS VTRGQRLAAG GGCLLLAALC FGLAALYAPV LLLRARKFAL LWSLGSALAL
   121  AGSALLRGGA ACGRLLRCEE APSRPALLYM AALGATLFAA LGLRSTLLTV LGAGAQVAAL
   181  LAALVGLLPW GGGTALRLAL GRLGRGAGLA KVLPV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SFT2D3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 4
Mean surface accessibility (rSASA): 0.5
Highest tissue expression: 5.8 nTPM

Expression across tissuesHPA

Tissue

epididymis: 5.8 nTPM
liver: 5.6 nTPM
rectum: 5.1 nTPM
breast: 4.8 nTPM
parathyroid gland: 4.7 nTPM
tonsil: 4.5 nTPM

Single-cell type

retinal pigment epithelial cells: 34 nCPM
late primary spermatocytes: 22 nCPM
cardiomyocytes: 15 nCPM
epididymal principal cells: 15 nCPM
respiratory deuterosomal cells: 14 nCPM
prostatic glandular cells: 13 nCPM

Immune cell

NK-cell: 0.2 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

midbrain: 0.2 nTPM
amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.87
gnomAD pLI: 0.1
gnomAD missense Z: -1.49
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SFT2D3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

RAB2A

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SFT2D3 as an antibody target. Whether an autoantibody or antibody against SFT2D3 could matter depends on whether native SFT2D3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SFT2D3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SFT2D3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...